文献速递血管炎

队列研究揭示心肌炎是大血管炎罕见且危及生命的首发表现

A cohort study reveals myocarditis to be a rare and life-threatening presentation of large vessel vasculitis.
PubMed 文献 · Semin Arthritis Rheum · 2017-04-04

BACKGROUND: The predominant forms of adult large vessel vasculitis (LVV) are giant cell arteritis (GCA) and Takayasu arteritis (TA). Cardiac involvement in LVV is a cause of morbidity and mortality, particularly in TA.…

要点

  • 大血管炎以心肌炎起病罕见但严重,本队列发生率为2.8%。
  • 超声心动图和心脏磁共振可诊断并监测心肌炎治疗反应。
  • 初始积极免疫抑制治疗可显著改善左心室射血分数和心脏状态。

核心结论

  • 大血管炎中临床显著的心肌炎罕见但严重,非侵入性影像可替代心肌活检,初始积极免疫抑制治疗可显著改善左心室射血分数和心脏状态。

研究设计与样本

  • 回顾性分析Imperial College大血管炎数据库,纳入139例大动脉炎和24例巨细胞动脉炎患者。

主要发现

  • 起病时识别的心血管病变包括主动脉瓣反流11例、心肌炎4例和肾动脉狭窄所致高血压性心肌病1例。
  • 心肌炎4例(2.8%)经超声心动图和心脏磁共振诊断,所有4例左心室射血分数序列改善(p < 0.05)。
  • 泼尼松龙联合环磷酰胺治疗使3例心力衰竭症状和左心室射血分数显著改善。
  • 1例环磷酰胺禁忌者使用托珠单抗后心脏症状明显改善。

关键数值与推荐

  • 心肌炎诊断依据超声心动图和心脏磁共振,足以诊断临床显著心肌炎。

临床怎么用

  • 对大血管炎起病时心力衰竭患者应警惕心肌炎,可用超声心动图和心脏磁共振诊断并监测治疗反应。
  • 初始积极免疫抑制治疗(如泼尼松龙联合环磷酰胺)可改善左心室射血分数和心脏状态。
  • 环磷酰胺禁忌时可考虑托珠单抗治疗。

局限性

  • 回顾性数据库研究,样本来自单中心,心肌炎病例数少(4例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The predominant forms of adult large vessel vasculitis (LVV) are giant cell arteritis (GCA) and Takayasu arteritis (TA). Cardiac involvement in LVV is a cause of morbidity and mortality, particularly in TA. Cardiac failure is most commonly secondary to uncontrolled arterial hypertension or myocardial ischaemia. Pulmonary hypertension and aortic valve incompetence following ascending aortic dilatation represent other serious cardiovascular complications. However, cardiac failure as a consequence of myocarditis is rarely reported, principally in single case reports or in autopsy studies. METHODS: The Imperial College LVV database was, retrospectively, reviewed to identify patients with cardiac involvement at presentation. Patients with evidence for myocarditis were identified. The cardiac presentation, imaging studies and subsequent medical and surgical management were reviewed in detail. RESULTS: The cohort included 139 patients with TA and 24 with GCA. Sixteen presented with cardiac failure without a history of ischaemic coronary heart disease, 14 (10%) with TA and 2 (8.3%) with GCA. Cardiovascular disease identified at presentation included aortic regurgitation (n = 11), myocarditis (n = 4) and hypertensive cardiomyopathy secondary to renal artery stenosis (n = 1). Those patients with evidence of myocarditis at presentation (2.8%) underwent transthoracic echocardiography and cardiac magnetic resonance imaging (CMR). These non-invasive techniques were sufficient for diagnosis of clinically significant myocarditis. Furthermore, they were subsequently used to monitor response to treatment, with serial improvement in left ventricular ejection fraction (LVEF) observed in all 4 patients (p < 0.05). Prednisolone plus cyclophosphamide (CyC) therapy was associated with significant improvement in heart failure symptoms and LVEF in 3 cases. In one case where CyC was contraindicated, tocilizumab treatment led to marked improvement in cardiac symptoms. CONCLUSION: Clinically significant myocarditis in LVV remains a rare but serious presentation. Non-invasive imaging techniques offer an alternative to the gold-standard myocardial biopsy. Initial aggressive immunosuppressive therapy is recommended and led to significant improvements in LVEF and cardiac status.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Bechman K, Gopalan D, Nihoyannopoulos P, et al. A cohort study reveals myocarditis to be a rare and life-threatening presentation of large vessel vasculitis. Semin Arthritis Rheum. 2017. PMID: 28502640. doi:10.1016/j.semarthrit.2017.03.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。